Combination Therapy for the Treatment of Uveal Melanoma

The synergistic use of Compound PAC-1 and kinase inhibitors like entrectinib induces apoptotic cell death in uveal melanoma, addressing the cancer's evasion of apoptosis and providing a promising treatment for metastatic uveal melanoma.

JP7591283B2Active Publication Date: 2024-11-28THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
JP2021518475
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-10-05
Filing Date
2019-10-03
Publication Date
2024-11-28
Estimated Expiration
2039-10-03

AI Technical Summary

Technical Problem

Current treatments for uveal melanoma, particularly metastatic forms, are ineffective, with a high mortality rate and limited survival rates due to the cancer's ability to evade apoptotic cell death through autophagic protection, and there are no targeted drug therapies available.

Method used

The combination of Compound PAC-1, which directly activates procaspase 3, with kinase inhibitors such as entrectinib, synergistically induces apoptotic cell death in uveal melanoma cells while sparing normal cells.

Benefits of technology

This combination effectively kills uveal melanoma cells with minimal impact on normal cells, offering a potential therapeutic strategy for improving survival rates and treating metastatic uveal melanoma.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007591283000012
    Figure 0007591283000012
  • Figure 0007591283000013
    Figure 0007591283000013
  • Figure 0007591283000014
    Figure 0007591283000014
Patent Text Reader

Abstract

A synergistic drug combination with the small molecule PAC-1 for uveal or cutaneous melanoma was demonstrated. There are currently no targeted drug treatments for mutations associated with uveal melanoma. Despite primary radiation therapy or surgical treatment, up to 50% of patients ultimately develop metastatic disease, and no standard treatment exists for this disease or a treatment shown to improve overall survival. Drug combinations with PAC-1 allow for the use of lower doses of this compound, which results in cancer cell death in uveal melanoma. Drug combinations with PAC-1 and the kinase inhibitor entrectinib demonstrated synergistic activity against uveal melanoma cell lines. Specifically, PAC-1 and entrectinib are synergistic against wild-type and mutant uveal melanoma cell lines (e.g., GNAQ and GNA11).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 62 / 742,063, filed October 5, 2018, which is incorporated herein by reference.

[0002] Government support This invention was made with Government support under Grant No. R01-CA120439 awarded by the National Institutes of Health. The Government has certain rights in the invention. [Background technology]

[0003] Uveal melanoma (UM) is the most common form of ocular melanoma. Approximately 97% of UM patients harbor activating mutations in GNAQ / 11, leading to constitutive activation of GNAQ / 11 signaling and driving the UM phenotype. Although the cell biology of UM has been extensively studied in the literature, this extensive knowledge has not directly translated into better treatment and outcomes for UM patients. Primary UM tumors can typically be managed with a combination of radiation therapy and surgery, but 51% of UM patients will present with metastatic disease within 1–5 years. Metastatic uveal melanoma (MUM), typically located in the liver, is a highly aggressive cancer associated with an overall 1-year survival rate of less than 15%.

[0004] Current research in this field is focused on utilizing single agent or combination kinase inhibitors targeting downstream of GNAQ / 11. Most notable of these, MEK inhibition with selumetinib showed promising response rates in phase II clinical trials but failed to achieve its clinical endpoint in phase III trials. Interestingly, there is evidence that UM avoids potent apoptotic cell death in response to kinase inhibitors via autophagy protection. Prevention of this potent cell death may translate to reduced efficacy in the clinic.

[0005] There are no current targeted drug treatments for mutations associated with uveal melanoma and UM. Therefore, there is a need for effective standard therapies or treatments that can improve overall survival in patients with UM. Summary of the Invention

[0006] Given the evidence showing that uveal melanoma avoids robust apoptotic cell death in response to kinase inhibitors via autophagy protection, direct activation of procaspase 3 in combination with kinase inhibition was explored to induce high levels of apoptotic cell death in uveal melanoma. The combination of PAC-1 and specific kinase inhibitors was found to effectively kill melanoma cells with little or no effect on normal (non-cancerous) cells. Thus, the present disclosure provides (a) Compound PAC-1: [ka] (b) at least one second active agent, the second active agent being an inhibitor of a tyrosine kinase, an inhibitor of adenosine monophosphate-activated protein kinase (AMPK), or a combination thereof; and (c) optionally, a pharma- ceutically acceptable diluent, excipient, carrier, or combination thereof; A composition comprising:

[0007] In some embodiments, the second active agent is entrectinib, dorsomorphin, or a combination thereof.

[0008] The present disclosure also provides a method of inhibiting the growth or proliferation of (melanoma) cancer cells, comprising contacting the cancer cells with an effective amount of a composition described herein, thereby inhibiting the growth or proliferation of the cancer cells. Additionally, the present disclosure provides a method of inducing apoptosis in melanoma cells, comprising contacting the cells with an effective amount of a composition described herein, thereby inducing apoptosis in the melanoma cells.

[0009] The present disclosure also provides a method for treating cancer, such as melanoma, comprising administering to a patient in need thereof a therapeutically effective amount of compound PAC-1 and an effective amount of a second active agent simultaneously or sequentially, thereby optionally forming the above-mentioned composition systemically, thereby treating cancer.In various embodiments, the cancer is uveal melanoma or cutaneous melanoma.

[0010] Thus, the present invention provides novel compositions and compositions for the manufacture of medicaments useful for the treatment of cancer in mammals, such as adult or non-adult humans.

[0011] The present invention provides the use of the compositions described herein for use in medical therapy. The medical therapy can treat cancer, such as skin cancer (melanoma) or eye cancer (uveal melanoma). The present invention also provides the use of the compositions described herein for the manufacture of a medicament for treating disease in a mammal, such as melanoma in a human. The medicament can include a pharmaceutically acceptable diluent, excipient, or carrier.

[0012] The following drawings form part of this specification and are included to further demonstrate certain embodiments or various aspects of the present invention. In some cases, embodiments of the present invention can be best understood by referring to the accompanying drawings in combination with the detailed description presented herein. This description and the accompanying drawings may highlight certain specific examples or particular aspects of the present invention. However, those skilled in the art will understand that some of the examples or aspects may be used in combination with other examples or aspects of the present invention. [Brief description of the drawings]

[0013] [Figure 1] Relative expression of procaspase 3 (PC-3) across a panel of uveal melanoma cell lines. [Diagram 2]Percentage of cell death observed when the UM cell line MEL270 was treated with a combination of PAC-1 and small molecule inhibitors by incubation for 72 hours. MEL270 is a GNAQ mutant cell line. Data from the PAC-1 + entrectinib combination are shown in the boxes. Data shown are the average of two independent experiments. [Diagram 3] PAC-1 in combination with entrectinib shows synergy across a panel of UM cell lines. Cell death and corresponding CI values ​​were calculated after 72 h of incubation. Cell lines are displayed by their driver mutations. CI values ​​<1 are synergistic, with lower values ​​representing higher levels of synergy. CI values ​​= 1 indicate additivity. CI values ​​> 1 indicate antagonism between the two agents. Data shown are the mean of at least three independent experiments, except for H460KRAS cell line; errors are expressed as s.e.m.; 4,000 cells / well, alamar blue fluorescence; killing control: raptinar. [Figure 4] PAC-1 + entrectinib demonstrates broad synergy across a wide concentration range. Data shown are the mean of at least three independent replicates, with errors expressed as sem. [Diagram 5] PAC-1 + entrectinib has significant activity against UM cell lines. Mean CI was calculated by averaging cell death observed with 2 μM PAC-1 + 0.5 μM entrectinib, 2 μM PAC-1 + 1 μM entrectinib, 4 μM PAC-1 + 0.5 μM entrectinib, and 4 μM PAC-1 + 1 μM entrectinib. Unless otherwise stated, values ​​shown are the mean of at least two independent experiments and errors are sem of the mean. ◆ represents a result with N=1. [Figure 6]Data shown are the mean of at least three independent experiments; errors are expressed as sem; 4,000 cells / well, 72 h incubation, Alamar Blue fluorescence; Kill control: Raptinal. (A) PAC-1 and entrectinib synergize in UMGq. (B) PAC-1 and entrectinib synergize in UMG11 / WT. (C) Interpretation of Combination Index (CI):

number

[0014] Members of the caspase family of cysteine ​​proteases play key roles in both the initiation and execution of apoptosis. Most critical for apoptosis is the proteolytic conversion of procaspase 3 to caspase 3. Because both intrinsic and extrinsic apoptotic pathways converge to activate procaspase 3, and caspase 3 has over 100 cellular substrates, activation of procaspase 3 to caspase 3 is a crucial and restrictive event in the apoptotic cascade. Procaspase 3 levels are elevated in a variety of tumors, including glioblastoma, breast cancer, colon cancer, lung cancer, lymphoma, neuroblastoma, melanoma, and liver cancer. Procaspase-activating compound 1 (PAC-1) is a small molecule that enhances procaspase 3 activity in vitro, induces apoptotic death of cancer cells in culture, and is effective in multiple mouse xenograft models. There is a strong correlation between cellular procaspase 3 levels and the apoptosis-inducing properties of PAC-1. As described herein, the combination of PAC-1 and specific kinase inhibitors has been found to effectively kill melanoma cells, with little or no effect on normal (non-cancerous) cells.

[0015] definition The following definitions are included to provide a clear and consistent understanding of the specification and claims. As used herein, the recited terms have the following meanings. All other terms and phrases used herein have their ordinary meanings as understood by those of ordinary skill in the art. Such ordinary meanings are defined in Hawley's Condensed Chemical Dictionary 14 by R. J. Lewis, John Wiley & Sons, New York, NY, 2001. th The terminology may be obtained by reference to a technical dictionary such as Edition.

[0016] References herein to "one embodiment," "one embodiment," and the like indicate that the embodiment being described may include a particular aspect, feature, structure, moiety, or characteristic, but not all embodiments necessarily include that aspect, feature, structure, moiety, or characteristic. Moreover, such phrases may, but do not necessarily, refer to the same embodiment as referenced elsewhere in this specification. Furthermore, when a particular aspect, feature, structure, moiety, or characteristic is described in connection with one embodiment, it is within the knowledge of one of ordinary skill in the art that it affects or connects to such aspect, feature, structure, moiety, or characteristic with respect to other embodiments, whether or not explicitly stated.

[0017] The singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, a reference to "a compound" includes a plurality of such compounds, such that a compound X includes a plurality of compounds X. Additionally, it should be noted that the claims may be drafted to exclude any element. Thus, this statement is intended to serve as a predicate for the use of exclusive terms such as "solely," "only," and the like in connection with the recitation or use of a "negative" limitation of any element described herein and / or claim elements.

[0018] The term "and / or" means any one of the items, any combination of the items, or all of the items with which the term is associated. The phrases "one or more" and "at least one" are readily understood by those of ordinary skill in the art, especially when read in the context of their usage. For example, the phrase can mean 1, 2, 3, 4, 5, 6, 10, 100, or an upper limit that is about 10, 100, or 1000 times higher than the stated lower limit.

[0019] As will be appreciated by those of ordinary skill in the art, all numerical values, including those expressing such properties as amounts of ingredients, molecular weights, reaction conditions, and the like, are approximate and may be modified in all instances by the term "about." These values ​​may vary depending on the desired properties one of ordinary skill in the art seeks to obtain using the teachings of the description herein. It is also understood that such values ​​inherently contain variability necessarily resulting from standard deviations found in their respective testing measurements. When values ​​are expressed as approximations, it will be understood that the particular value without the modifier "about" also forms a further aspect by using the antecedent "about."

[0020] The terms "about" and "approximately" are used interchangeably. Both terms can refer to a variation of ±5%, ±10%, ±20%, or ±25% of the specified value. For example, "about 50" percent can, in some embodiments, carry a variation of 45 to 55 percent, or as otherwise defined by a particular claim. In the case of integer ranges, the term "about" can include one or two integers greater than and / or less than the integers recited at each end of the range. Unless otherwise indicated herein, the terms "about" and "approximately" are intended to include values ​​close to the recited range, e.g., weight percent, that are equivalent with respect to the function of the individual components, compositions, or embodiments. The terms "about" and "approximately" can also modify the endpoints of the ranges recited, as described above in this paragraph.

[0021] As will be understood by those skilled in the art, for all purposes, particularly with respect to providing a written description, all ranges recited herein also encompass any and all possible subranges and combinations of subranges, as well as the individual values, particularly integer values, that make up the range. Thus, it is understood that each unit between two specific units is also disclosed. For example, if 10 to 15 is disclosed, 11, 12, 13, and 14 are also disclosed individually and as part of a range. A recited range (e.g., weight percent or carbon group) includes each specific value, integer, decimal, or identity within the range. A recited range can be easily recognized as fully describing and allowing the same range to be broken down into at least 2, 3, 4, 5, or 10 equal parts. As a non-limiting example, each range discussed herein can be easily broken down into a lower third, a middle third, and an upper third, etc. As will also be appreciated by those skilled in the art, all language such as "up to," "at least," "greater than," "less than," "more than," "greater than," and "greater than" includes the recited numbers, and such terms refer to ranges that can later be broken down into subranges as discussed above. Similarly, all ratios recited herein include all subratios that fall within the broader ratio. Thus, the specific values ​​recited for radicals, substituents, and ranges are for illustrative purposes only; they do not exclude other defined values ​​for radicals and substituents or other values ​​within the defined ranges. Moreover, it will be understood that the endpoints of each range are meaningful with respect to the other endpoint and independently of the other endpoint.

[0022] Those skilled in the art will also readily recognize that when members are grouped together in a common manner, such as a Markush group, the invention encompasses not only the entire group recited as a whole, but also each member of the group individually, and all possible subgroups of the main group. Moreover, for all purposes, the invention encompasses not only the main group, but also the main group in which one or more group members are absent. Thus, the invention contemplates the explicit exclusion of any one or more members of a recited group. Thus, provisos may be applied to any of the disclosed categories or embodiments, whereby any one or more of the recited elements, species, or embodiments may be excluded from such category or embodiment, for example, for use in an express negative limitation.

[0023] The term "contacting" refers to the act of touching, contacting, or bringing into close or proximity, including at the cellular or molecular level, e.g., in a solution, in a reaction mixture, in vitro, or in vivo, to effect a physiological reaction, a chemical reaction, or a physical change.

[0024] "Effective amount" refers to an amount effective for treating a disease, disorder, and / or condition, or for producing a described effect. For example, an effective amount can be an amount effective for reducing the progression or severity of the condition or symptom being treated. Determination of a therapeutically effective amount is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein. The term "effective amount" is intended to include, for example, an amount of a compound described herein, or an amount of a combination of compounds described herein, that is effective for treating or preventing a disease or disorder in a host, or treating a symptom of a disease or disorder. Thus, "effective amount" generally refers to an amount that provides a desired effect.

[0025] Alternatively, the term "effective amount" or "therapeutically effective amount" as used herein refers to a sufficient amount of an agent or composition or combination of compositions administered that relieves to some extent one or more of the symptoms of the disease or condition being treated. The result can be reduction and / or alleviation of the signs, symptoms, or causes of the disease, or other desired change in a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition containing a compound as disclosed herein that is required to provide a clinically significant reduction in a symptom of the disease. An appropriate "effective" amount in an individual case can be determined using techniques such as dose escalation studies. The dose can be administered in one or more administrations. However, the precise determination of what is considered an effective dose can be based on factors individual to each patient, including, but not limited to, the patient's age, size, type or extent of the disease, stage of the disease, route of administration of the composition, type or extent of supplemental therapy used, ongoing disease process, and type of treatment desired (e.g., aggressive treatment vs. conventional treatment).

[0026] The terms "treating", "treat" and "treatment" include (i) preventing the occurrence of a disease, pathological or medical condition (e.g., prophylaxis); (ii) inhibiting or arresting the development of a disease, pathological or medical condition; (iii) alleviating a disease, pathological or medical condition; and / or (iv) alleviating symptoms associated with a disease, pathological or medical condition. Thus, the terms "treat", "treatment" and "treating" can extend to prophylaxis and can include preventing, prophylactic, preventing, reducing, arresting or reversing the progression or severity of the condition or symptom being treated. Thus, the term "treatment" can include medical, therapeutic, and / or prophylactic administration, as appropriate.

[0027] As used herein, "subject" or "patient" refers to an individual who has symptoms of or is at risk for a disease or other malignancy. A patient may be a human or a non-human animal, and may include, for example, animal strains or species used as "model systems" for research purposes, such as the mouse model described herein. Similarly, a patient may include either an adult or a young (e.g., a child). Furthermore, a patient may refer to any organism, preferably a mammal (e.g., a human or a non-human animal), that may benefit from administration of the compositions contemplated herein. Examples of mammals include, but are not limited to, any member of the mammalian class: humans, non-human primates such as chimpanzees and other apes, and monkey species; domestic animals such as cows, horses, sheep, goats, pigs; domestic animals such as rabbits, dogs, and cats; and laboratory animals, including rodents such as rats, mice, and guinea pigs. Examples of non-mammals include, but are not limited to, birds, fish, and the like. In one embodiment of the methods provided herein, the mammal is a human.

[0028] As used herein, the terms "providing," "administering," and "introducing" are used interchangeably herein and refer to placing a composition of the present disclosure within a subject by a method or route that results in at least partial localization of the composition at a desired site. The composition can be administered by any suitable route that results in delivery to the desired location within the subject.

[0029] The compositions described herein may be administered with additional compositions to prolong the stability and activity of the composition, or in combination with other therapeutic agents.

[0030] The terms "inhibit," "inhibiting," and "inhibition" refer to slowing, stopping, or reversing the growth or progression of a disease, infection, condition, or cell population. Inhibition can be, for example, greater than about 20%, 40%, 60%, 80%, 90%, 95%, or 99% compared to the growth or progression that occurs in the absence of treatment or contact.

[0031] The term "substantially" as used herein is a broad term and is used in its ordinary sense, including, without limitation, that which is primarily, but not necessarily entirely, specified. For example, the term may refer to a value that may not be 100% of the complete value. The complete value may be about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, or about 20% less.

[0032] Uveal melanoma. The term "uveal melanoma" refers to ocular cancers (melanomas) that involve parts of the eye collectively referred to as the uvea. Uveal melanoma arises from the uvea of ​​the eye, which includes the choroid, ciliary body, and iris. The tumors typically arise from pigment cells (melanocytes) that reside within the uvea. Uveal melanoma is the most common primary intraocular malignancy in adults. It is biologically distinct from cutaneous melanoma and accounts for approximately 3%-5% of all melanomas. Currently, there are no approved or effective systemic treatment options for individuals with metastatic uveal melanoma. Mutations in GNAQ or GNA11 are found in 80% of uveal melanomas, resulting in constitutive activation of the RAS / RAF / MEK / ERK pathway.

[0033] Because true iris melanomas, which arise within the iris rather than originating elsewhere and invading the iris, have a different etiology and prognosis, the other tumors are often collectively referred to as posterior uveal melanomas.Iris melanomas have more in common with cutaneous melanomas in that they frequently harbor BRAF mutations associated with ultraviolet radiation damage.

[0034] Cutaneous melanoma is cancer that begins in the skin's pigment-producing cells known as melanocytes, while noncutaneous melanomas appear in places not typically thought of as skin, such as the eye, inside the nose, or mucous membranes (such as the lining of the mouth, intestine, vagina, anus, or rectum).

[0035] EMBODIMENTS OF THE PRESENTINVENTION The present disclosure relates to (a) Compound PAC-1: [ka] (b) at least one second active agent, the second active agent being an inhibitor of a tyrosine kinase, an inhibitor of adenosine monophosphate-activated protein kinase (AMPK), or a combination thereof; and (c) optionally, a pharma- ceutically acceptable diluent, excipient, carrier, or combination thereof; Various embodiments of the composition are provided comprising:

[0036] In some embodiments, the second active agent is an inhibitor of neurotrophic receptor tyrosine kinase (NTRK), C-ros oncogene 1 (ROS1), anaplastic lymphoma kinase (ALK), or a combination thereof. In other embodiments, the second active agent is an inhibitor of tropomyosin receptor kinase A (TrkA), tropomyosin receptor kinase B (TrkB), tropomyosin receptor kinase C (TrkC), or a combination thereof. In further embodiments, the second active agent is an inhibitor of Janus kinase 1 (JAK1), Janus kinase 2 (JAK2), Janus kinase 3 (JAK3), activated CDC42 kinase 1 (ACK1), insulin-like growth factor 1 receptor (IGF1R), focal adhesion kinase (FAK), fms-like tyrosine kinase 3 (FLT3), breast tumor kinase (BRK), insulin receptor (IR), Aurora 2 kinase (AUR2), RET receptor tyrosine kinase (RET), non-receptor tyrosine protein kinase 1 (TNK1), or a combination thereof.

[0037] In further embodiments, the second active agent is entrectinib. In yet other embodiments, the second active agent is dorsomorphin. In further embodiments, the second active agent is linsitinib or VS-4718 (PND-1186). In further various embodiments, the second active agent is R1507, MK0646, OSI-906, BIIB022, figitumumab (CP-751,871), AXL1717, AMG479, alectinib, sunitinib, imatinib, sorafenib, nilotinib, bevacizumab, ipilimumab, cixutumumab, or combinations thereof.

[0038] In various embodiments, the second active agent is an inhibitor as shown for the target in Table A (below): [Table 1]

[0039] In various embodiments, the second active agent may be one or more compounds disclosed in U.S. Patent No. 8,299,057, and these compounds and the formulas describing them are incorporated herein by reference. In further various embodiments, the second active agent is an inhibitor of IGF1R, and the IGF1R inhibitor is AG538, AG1024, NVP-AEW541, or figitumumab. In other various embodiments, the second active agent is an inhibitor of FAK (or protein tyrosine kinase 2 (PTK2)), and the FAK inhibitor is PF-573,228, PF-562,271, NVP-226, Y15, defactinib, or VS-6063. In various embodiments, the second active agent may be administered in an amount that is synergistic with PAC-1 for the treatment of uveal or cutaneous melanoma.

[0040] In various embodiments, PAC-1 and / or the second active agent are administered orally, intravenously, subcutaneously, by inhalation, intramuscularly, intravitreally, or by any route known to one of skill in the art.

[0041] In various other embodiments of the compositions disclosed above, the concentration of the second active agent is from about 1 nM to about 100 μM. In further embodiments, the concentration of the second active agent is from about 1 nanomolar to about 10,000 nanomolar. In still other embodiments, the concentration of PAC-1 is from about 0.1 μM to about 50 μM. In further embodiments, the concentration of PAC-1 is from about 1 μM to about 15 μM. In still some other embodiments, the concentration of PAC-1 is from about 1 μM to about 5 μM.

[0042] In further various embodiments, the systemic concentrations of PAC-1 and the second active agent (SAA) are as set forth in Table B. * Shown below: [Table 2]

[0043] The present disclosure further provides the above compositions, wherein a) the carrier comprises water, a buffer, a sugar, a cellulose, a cyclodextrin, dimethylsulfoxide, polyethylene glycol, a tocopherol, a liposome, a micelle, or a combination thereof, and / or b) the excipient comprises a binder, a lubricant, an adsorbent, a vehicle, a disintegrant, a preservative, or a combination thereof.

[0044] The present disclosure provides a method of inhibiting the growth or proliferation of (melanoma) cancer cells, comprising contacting the cancer cells with an effective amount of a composition as disclosed herein, thereby inhibiting the growth or proliferation of the cancer cells. Additionally, the present disclosure provides a method of inducing apoptosis in (melanoma) cancer cells, comprising contacting the cancer cells with an effective amount of a composition as disclosed herein, thereby inducing apoptosis in the cancer cells.

[0045] Additionally, the present disclosure also provides a method of treating cancer (melanoma), comprising administering to a patient in need thereof a therapeutically effective amount of the compound PAC-1 and an effective amount of a second active agent, either simultaneously or sequentially, optionally systemically forming a composition as described herein, thereby treating the cancer. In various embodiments, PAC-1 is synergistic with the second active agent, and the second active agent is entrectinib, dorsomorphin, or a compound from Table A, and the concentrations of the agents can be those listed in Table B.

[0046] In various embodiments of the present disclosure, the cancer is uveal melanoma or cutaneous melanoma. In other embodiments, the uveal melanoma is GNAQ mutant, GNA11 mutant, GNAQ wild type, or GNA11 wild type uveal melanoma. In further embodiments, the resistance to cancer treatment in a patient who needs cancer treatment is reduced, delayed, or eliminated. In yet other embodiments, the metastasis of cancer in a patient who needs cancer treatment is reduced, delayed, or eliminated. The reduction, delay, or elimination of the metastasis of cancer can be determined by procedures known to those skilled in the art.

[0047] The present disclosure also provides a method of synergizing PAC-1 with a second active agent in vivo, comprising: a) the concentration of PAC-1 is from about 0.1 μM to about 50 μM and the concentration of the second active agent is from about 1 nM to about 100 μM; b) the concentration of PAC-1 is from about 1 μM to about 15 μM and the concentration of the second active agent is from about 1 nM to about 10,000 nM; or c) the concentration of PAC-1 is about 1 μM to about 5 μM and the concentration of the second active agent is about 1 nM to about 1000 nM; A method is provided.

[0048] In other embodiments of the disclosure herein, the concentration of PAC-1 is about 0.5 μM, about 1.5 μM, about 2 μM, about 2.5 μM, about 3 μM, about 3.5 μM, about 4 μM, about 4.5 μM, about 5 μM, about 6 μM, about 7 μM, about 8 μM, about 9 μM, or about 10 μM.

[0049] In some embodiments, the compound PAC-1 and the second active agent are administered simultaneously to the cancer patient. In other embodiments, the PAC-1 and the second active agent are administered sequentially to the cancer patient. In one embodiment, PAC-1 is administered to the cancer patient before the second active agent. In another embodiment, PAC-1 is administered to the cancer patient after the second active agent. In certain embodiments, the second active agent is entrectinib, dorsomorphin, linsitinib, VS-4718, or a combination thereof.

[0050] The present disclosure further provides the use of a composition or a combination of compositions disclosed herein for preparing a medicament for the treatment of melanoma.The composition can be a composition comprising PAC-1, a composition comprising a second active agent such as entrectinib, or a combination thereof, or a composition comprising PAC-1 and a second active agent.

[0051] In various embodiments, the melanoma is uveal melanoma or cutaneous melanoma. In further various embodiments, the uveal melanoma has a GNAQ mutation or GNA11 mutation, or is GNAQ wild type or GNA11 wild type.

[0052] In various embodiments, the doses, e.g., daily doses, of PAC-1 and the second active agent (SAA) are as set forth in Table C. * Shown below: [Table 3]

[0053] As will be appreciated by those of skill in the art, the recitation of a particular concentration or concentration range herein can be replaced with an appropriate dosage or dosage range, such as those listed in Table C above or discussed below, or ranges or range endpoints. In various embodiments, the amount of PAC-1 and the second active agent administered is an amount that is synergistic for the treatment of uveal or cutaneous melanoma.

[0054] In other embodiments, the total dose of PAC-1 is about 75 mg, about 150 mg, about 250 mg, about 375 mg, about 450 mg, about 625 mg, about 750 mg, or about 825 mg, and the total dose is administered once daily, twice daily, or three times daily.

[0055] The present disclosure provides various embodiments of a combination of a second active agent (SAA) and a compound PAC-1 for use in a method for treating cancer (e.g., melanoma) in a patient in need of such treatment, comprising administering a therapeutically effective amount of SAA and an effective amount of a compound PAC-1 simultaneously or sequentially to the patient, thereby treating the cancer. Another embodiment provides a composition of PAC-1 and a composition of entrectinib for use in a method for treating uveal or cutaneous melanoma in a patient in need of such treatment, comprising administering a therapeutically effective amount of a composition of PAC-1 and a therapeutically effective amount of a composition of entrectinib simultaneously or sequentially to the patient, thereby treating the uveal or cutaneous melanoma. The therapeutically effective amount can be an amount that is synergistic when administered for the treatment of uveal or cutaneous melanoma.

[0056] Another embodiment provides a combination of SAA and compound PAC-1 for said use, wherein SAA and compound PAC-1 are administered simultaneously. Another embodiment provides a combination of SAA and compound PAC-1 for said use, wherein SAA and compound PAC-1 are administered sequentially. Another embodiment provides a combination of SAA and compound PAC-1 for said use, wherein SAA is administered before compound PAC-1. Another embodiment provides a combination of SAA and compound PAC-1 for said use, wherein SAA is administered after compound PAC-1.

[0057] The disclosure provides ranges, limits, and deviations for variables such as volume, mass, percentages, ratios, etc. A range such as "1" to "2" is understood by one of ordinary skill in the art to mean a continuous range of numbers, including integers and decimals. For example, 1-10 means 1, 2, 3, 4, 5, ... 9, 10. It also means 1.0, 1.1, 1.2.1.3, ... 9.8, 9.9, 10.0, and 1.01, 1.02, 1.03, etc. When a disclosed variable is a number less than "10", it means a continuous range including integers and decimals less than 10, as discussed above. Similarly, when a disclosed variable is a number greater than "10", it means a continuous range including integers and decimals greater than 10. These ranges may be modified by the term "about", the meaning of which is explained above.

[0058] Results and Discussion Procaspase-3 activation strategies in UM cell lines. The procaspase-3 activating compound, PAC-1, has been shown to be a potent activator of procaspase-3 to active caspase-3 that induces apoptosis. UM cell lines express procaspase-3 (Figure 1) and PAC-1 has activity as a single agent in a panel of UM cell lines (Table D). [Table 4]

[0059] Current Treatment of Uveal Melanoma. There have been over 40 clinical trials reported in uveal melanoma, with a median response rate of 4%. The current standard of care is dacarbazine. In the recent randomized clinical SUMMIT trial of selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma, the objective response rate was 3% and progression-free survival was 2.8 months in the selumetinib plus dacarbazine treatment arm. The 3- and 6-month PFS rates were 38% and 10%, respectively. Overall survival was only 10 months.

[0060] Entrectinib. Entrectinib is a potent tyrosine kinase inhibitor that targets oncogene rearrangements in NTRK, ROS1, and ALK. Two phase I studies demonstrated activity in tyrosine kinase inhibitor-naive patients and substantial intracranial activity. In ROS1-rearranged lung cancer, entrectinib led to durable disease control and prolonged progression-free survival. The agent is well tolerated with a safety profile that includes adverse events mediated by on-target tropomyosin-related kinase A / B / C inhibition. The most common treatment-related adverse events of any grade were fatigue / asthenia (46%, n=55 / 119), dysgeusia (42%, n=50 / 119), dysesthesias (29%, n=34 / 119), nausea (28%, n=33 / 119), and myalgia (23%, n=27 / 119).

[0061] Combining PAC-1 with therapeutically relevant inhibitors. PAC-1 has been shown to synergize with a variety of clinically relevant drugs, including kinase inhibitors (Mol. Cancer Ther. 2016, 15, 1859; Cell Chem. Biol. 2018, 25, 996). We exploited this synergy by screening PAC-1 in combination with a variety of clinically relevant kinase inhibitors. The results of this biased screen are presented in Figure 2.

[0062] The combination of PAC-1 and entrectinib clearly stands out in this screen; for example, concentrations of PAC-1 and entrectinib that each result in approximately 16% killing as single agents induce 75% killing in combination (Figure 2). Entrectinib is a pan-TRK fusion, ALK fusion, and ROS1 fusion kinase inhibitor. These three fusion proteins are important driver alterations in multiple cancer types. Interestingly, these fusions, their parent kinases, and / or off-target kinases have not been reported as major oncogenic drivers in UM, potentially pointing to untapped therapeutic avenues for UM. To further explore this combination, the observed synergy was quantified across a panel of UM cell lines (Figure 3).

[0063] Interestingly, the greatest response (measured by cell death and CI values) was observed in the GNAQ / 11 cell line. Although cell death was less in GNAQ / 11 WT cells (MEL285 and MEL290), the CI values ​​were less than 1, suggesting synergy in these cell lines. This effect seen in mutant GNAQ UM cell lines was consistent across a wide range of PAC-1 and entrectinib concentrations (Figure 4).

[0064] Because the target of entrectinib in UM cells remains to be elucidated, we sought to determine whether this combination was synergistic across the panel of cancer cell lines (Figure 5). The combination of PAC-1 and entrectinib appears to be most effective and synergistic in the UM GNAQ / 11 mutant cell lines. The average CI values ​​in other melanoma cell lines were also less than 1, pointing to a synergistic combination, while other cancer cell lines evaluated did not show synergy (Figure 5). Importantly, the combination did not cause significant cell death and was not synergistic in HFF-1, a non-cancerous normal cell line.

[0065] The results described herein present a new strategy for the treatment of uveal melanoma. The combination of PAC-1 and entrectinib has proven to be an exciting prospect for the clinical treatment of uveal and cutaneous melanoma. Entrectinib has completed two Phase I clinical trials with promising activity and limited toxicity in patients, and PAC-1 is currently undergoing Phase I clinical trials in humans. Thus, combination therapy of entrectinib and PAC-1 is expected to provide an effective clinical treatment of uveal melanoma and closely related cancers.

[0066] Pharmaceutical preparations The compounds described herein can be used to prepare therapeutic pharmaceutical compositions, for example by combining the compounds with pharma- ceutically acceptable diluents, excipients, or carriers. The compounds can be added to the carrier in the form of salts or solvates. For example, if the compounds are sufficiently basic or acidic to form stable non-toxic acid or base salts, administration of the compounds as salts can be appropriate. Examples of pharma-ceutically acceptable salts are organic acid addition salts formed with acids that form physiologically acceptable anions, such as tosylate, methanesulfonate, acetate, citrate, malonate, tartrate, succinate, benzoate, ascorbate, α-ketoglutarate, and β-glycerophosphate. Suitable inorganic salts can also be formed, including hydrochloride, halide, sulfate, nitrate, bicarbonate, and carbonate.

[0067] Pharmaceutically acceptable salts can be obtained, using standard procedures well known in the art, by reacting a sufficiently basic compound, such as an amine, with a suitable acid to provide a physiologically acceptable ionic compound. Alkali metal (e.g., sodium, potassium or lithium) or alkaline earth metal (e.g., calcium) salts of carboxylic acids can also be prepared by similar methods.

[0068] The compounds of the formulae described herein can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient, in a variety of forms that can be specifically adapted for a selected route of administration, for example oral or parenteral administration by intravenous, intramuscular, topical or subcutaneous routes.

[0069] The compounds described herein may be administered systemically in combination with a pharma- ceutically acceptable vehicle, such as an inert diluent or an assimilable edible carrier. For oral administration, the compounds may be enclosed in hard or soft shell gelatin capsules, compressed into tablets, or incorporated directly into the food of the patient's diet. The compounds may also be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations typically contain at least 0.1% of active compound. The percentage of the compositions and preparations may vary and may conveniently be about 0.5% to about 60%, about 1% to about 25%, or about 2% to about 10% by weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions may be an amount that allows an effective dosage level to be obtained.

[0070] Tablets, troches, pills, capsules, etc. may also contain one or more of the following: binders such as gum tragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; disintegrating agents such as corn starch, potato starch, alginic acid; and lubricants such as magnesium stearate. Sweeteners such as sucrose, fructose, lactose, or aspartame; or flavorings such as peppermint, wintergreen oil, or cherry flavor may be added. When the unit dosage form is a capsule, in addition to the above types of materials, it may contain liquid carriers such as vegetable oils or polyethylene glycol. Various other materials may be present as coatings or to modify the physical form of the solid unit dosage form. For example, tablets, pills, or capsules may be coated with gelatin, wax, shellac, sugar, and the like. Syrup or elixir may contain the active compound, sucrose or fructose as a sweetener, methyl and propylparabens as preservatives, dyes, and flavorings such as cherry or orange flavor. Any material used in preparing any unit dosage form should be pharma- ceutically acceptable and substantially non-toxic in the amounts used. Moreover, the active compounds may be incorporated into sustained-release preparations and devices.

[0071] The active compound can be administered intravenously or intraperitoneally by infusion or injection.The solution of the active compound or its salt can be prepared in water, and can be mixed with non-toxic surfactants.Dispersion can be prepared in glycerol, liquid polyethylene glycol, triacetin, or mixtures thereof, or in pharmaceutically acceptable oil.Under normal storage and use conditions, the preparation can contain a preservative to prevent the growth of microorganisms.

[0072] Pharmaceutical dosage forms suitable for injection or infusion may include sterile aqueous solutions, dispersions, or sterile powders containing the active ingredient adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, which may be encapsulated in liposomes. The final dosage form should be sterile, fluid, and stable under the conditions of manufacture and storage. The liquid carrier or vehicle may be a solvent or liquid dispersion medium, including, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol, etc.), vegetable oils, non-toxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions, or by the use of surfactants. Prevention of the action of microorganisms can be brought about by various antibacterial and / or antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it is preferable to include isotonic agents, for example, sugars, buffers, or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by agents delaying absorption, for example, aluminum monostearate and / or gelatin.

[0073] Sterile injectable solution can be prepared by incorporating the active compound in the required amount in a suitable solvent together with various other ingredients listed above as required, and then sterilized by filtration.For the preparation of sterile powder for sterile injectable solution, the preparation method can include vacuum drying and freeze-drying technology, which produces powder of active ingredient and any additional desired ingredient present in the solution.

[0074] For topical administration, the compounds may be applied in pure form, for example when they are liquids. However, it is generally desirable to administer the active agent to the skin as a composition or formulation in combination with a dermatologically acceptable carrier, which may be, for example, a solid, liquid, gel, etc.

[0075] Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina, etc. Useful liquid carriers include water, dimethyl sulfoxide (DMSO), alcohol, glycol, or water-alcohol / glycol blends, optionally with non-toxic surfactants, in which the compound can be dissolved or dispersed at effective levels. Adjuvants such as fragrances and additional antibacterial agents can be added to optimize the properties for a given application. The resulting liquid composition can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.

[0076] Thickening agents such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified cellulose, or modified mineral materials may also be used with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like for application directly to the user's skin.

[0077] Examples of dermatological compositions for delivering active agents to the skin are known in the art, see, for example, U.S. Patent No. 4,992,478 (Geria), U.S. Patent No. 4,820,508 (Wortzman), U.S. Patent No. 4,608,392 (Jacquet et al.), and U.S. Patent No. 4,559,157 (Smith et al.). Such dermatological compositions can be used in combination with the compounds described herein, where any component of such compositions can be replaced with the compounds described herein or the compounds described herein can be added to the composition.

[0078] The useful dosage of the compounds and compositions described herein can be determined by comparing their in vitro activity and in vivo activity in animal models.Methods for extrapolating effective dosages in mice and other animals to humans are known in the art, see, for example, U.S. Patent No. 4,938,949 (Borch et al.).The amount of compound or its active salt or derivative required for therapeutic use varies not only with the specific compound or salt selected, but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and is ultimately left to the discretion of the attending physician or clinician.

[0079] In general, however, a suitable dosage will be in the range of about 0.5 to about 100 mg per kilogram of recipient body weight per day, e.g., about 10 to about 75 mg / kg / day, e.g., 3 to about 50 mg / kg / day, preferably in the range of 6 to 90 mg / kg / day, most preferably in the range of 15 to 60 mg / kg / day.

[0080] The compounds are conveniently formulated in unit dosage form, for example containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently 50 to 500 mg of active ingredient per unit dosage form, hi one embodiment, the invention provides a composition comprising a compound of the invention formulated in such a unit dosage form.

[0081] The compound may be, for example, 5 to 1000 mg / m per unit dosage form. 2, advantageously 10 to 750 mg / m 2 , most conveniently 50-500 mg / m 2 The desired dose can be conveniently presented in a unit dosage form containing the active ingredient of. The desired dose can be conveniently presented in a single dose or as a divided dose administered at appropriate intervals, for example, as two, three, four or more partial doses per day. The partial dose itself can be further divided, for example, into several separate loosely spaced administrations.

[0082] The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, e.g., two, three, four or more partial doses per day. The partial dose itself may be further divided, e.g., into several discrete loosely spaced administrations, such as multiple inhalations from an insufflator or application of a number of drops to the eye.

[0083] The compounds and compositions described herein may be effective as anti-cancer agents when used alone to treat cancer at standard effective single agent doses and may have greater efficacy and / or less toxicity compared to, for example, entrectinib.

[0084] The present invention provides a therapeutic method for treating cancer in a mammal (or vertebrate), which includes, for example, administering to a mammal having cancer an effective amount of a compound or composition as described herein. Mammals include primates, humans, rodents, dogs, cats, cows, sheep, horses, pigs, goats, cattle, etc. Cancer refers to various types of malignant neoplasms, such as colon cancer, breast cancer, (uveal) melanoma, and leukemia, and is generally characterized by unwanted cell proliferation, such as unregulated growth, lack of differentiation, local tissue invasion, and metastasis.

[0085] The ability of the compounds of the present invention to treat cancer can be determined by using assays well known in the art, such as the design of treatment protocols, toxicity assessment, data analysis, quantification of tumor cell killing, and the biological significance of using transplantable tumor screening.

[0086] The following examples are intended to illustrate the above invention and should not be construed as limiting its scope. Those skilled in the art will readily recognize that the examples suggest many other ways in which the invention can be practiced. It should be understood that numerous variations and modifications can be made while remaining within the scope of the invention. EXAMPLES

[0087] example Example 1. Clinical trials. PAC-1 was administered to 34 human patients at seven dose levels of PAC-1 (range: 75-750 mg). Two patients progressed during the first cycle of PAC-1 therapy. Thirty-two patients received PAC-1 for at least two dosing cycles (a cycle is 21 days of daily dosing followed by 7 days without drug). Six patients received PAC-1 for four cycles, three patients received PAC-1 for six cycles, and two patients received PAC-1 for ten cycles as a result of stable disease response. No serious adverse events (SAEs) associated with PAC-1 administration were observed. Furthermore, after careful review of all neurological and neurocognitive evaluations as well as data collected through dose level 7 (750 mg), there were no conclusive signs of neurotoxicity associated with PAC-1 administration. Nonetheless, the brain tissue changes observed in both GLP canine PK / preclinical PAC-1 toxicity studies highlight the need for continued neurological and neurocognitive testing and constant monitoring in detecting neurological changes that may be associated with PAC-1 exposure.

[0088] Preclinical Data on Entrectinib and PAC-1 Activity in Uveal Melanoma In vitro testing of the combination of PAC-1 and entrectinib was performed in seven uveal melanoma cell lines (GNAQ mutant; MEL270, 92.1, MEL202, OMM2.5, GNA11 mutant: OMM1, and GNAQ and GNA11 wild type: MEL285 and MEL290). Synergistic killing effects of PAC-1 and entrectinib were observed in all seven cell lines. Entrectinib appears to synergize with PAC-1 in human patients with metastatic melanoma, resulting in superior progression-free survival.

[0089] Objectives and Endpoints Determination of progression-free survival (PFS) rates using RECIST v1.1 in subjects with metastatic uveal melanoma treated with entrectinib and PAC-1 is ongoing (Table 1). Safety of entrectinib in combination with PAC-1, as assessed by the incidence and severity of drug-related adverse events (AEs), is being evaluated in subjects with metastatic uveal melanoma. Determination of objective response rates [complete response (CR) + partial response (PR)] using RECIST v.1.1 and imaging in subjects with metastatic uveal melanoma treated with entrectinib and PAC-1 is ongoing. Duration of response using RECIST v1.1 in subjects with metastatic uveal melanoma is being determined. Overall survival (OS) rates are being determined in subjects with metastatic uveal melanoma treated with entrectinib and PAC-1. Work is ongoing to determine the expression of procaspase 3 in uveal melanoma tissues and the correlation between the presence of DNAQ and DNA11 mutations and procaspase 3 expression. [Table 5] [Table 6]

[0090] Example 2. Pharmaceutical dosage forms. The following formulations, hereinafter referred to as "Composition X", each optionally in the form of a pharma- ceutically acceptable salt or solvate, and each optionally in combination with one or more pharma- ceutically acceptable diluents, excipients, or carriers, illustrate representative pharmaceutical dosage forms that may be used for therapeutic administration of the compounds described herein or compounds of the formulas described herein. Composition X can contain a single agent (e.g., PAC-1 or entrectinib), or Composition X can contain a combination of two or more active agents (e.g., PAC-1 and entrectinib). The dosage amounts below are merely representative. The amounts of active agents and other components in each formulation can be adjusted (e.g., substantially proportionally) to fit larger or smaller dosage units, or the amounts of active agents in each formulation can be adjusted higher or lower to fit larger or smaller dosage units while maintaining the relative proportions of the other components at the levels described.

[0091] (i) 1 tablet mg / tablet "Composition X" 100.0 Lactose 77.5 Povidone 15.0 Croscarmellose sodium 12.0 Microcrystalline Cellulose 92.5 Magnesium stearate 3.0 300.0 (ii) Tablet 2 mg / tablet "Composition X" 20.0 Microcrystalline Cellulose 410.0 Starch 50.0 Sodium starch glycolate 15.0 Magnesium stearate 5.0 500.0 (iii) Capsules mg / capsule "Composition X" 10.0 Colloidal silicon dioxide 1.5 Lactose 465.5 Pregelatinized starch 120.0 Magnesium stearate 3.0 600.0 (iv) Injection 1 (1 mg / mL) mg / mL "Composition X" (free acid type) 1.0 Sodium phosphate dibasic 12.0 Sodium phosphate monobasic 0.7 Sodium chloride 4.5 1.0N sodium hydroxide solution (appropriate amount) (Adjust pH to 7.0-7.5) Water for injection: Enough to make 1 mL (v) Injection 2 (10 mg / mL) mg / mL "Composition X" (free acid type) 10.0 Sodium phosphate monobasic 0.3 Sodium phosphate dibasic 1.1 Polyethylene glycol 400 200.0 0.1N sodium hydroxide solution (appropriate amount) (Adjust pH to 7.0-7.5) Water for injection: Enough to make 1 mL (vi) Aerosols mg / can "Composition X" 20 Oleic Acid 10 Trichloromonofluoromethane 5,000 Dichlorodifluoromethane 10,000 Dichlorotetrafluoroethane 5,000 (vii) Topical gel 1 weight% "Composition X" 5% Carbomer 934 1.25% Triethanolamine (appropriate amount) (Adjust pH to 5-7) Methylparaben 0.2% Purified water (enough to make 100g) (viii) Topical gel 2 weight% "Composition X" 5% Methylcellulose 2% Methylparaben 0.2% Propylparaben 0.02% Purified water (enough to make 100g) (ix) Topical ointment weight% "Composition X" 5% Propylene glycol 1% Anhydrous ointment base 40% Polysorbate 80 2% Methylparaben 0.2% Purified water (enough to make 100g) (x) Topical cream 1 weight% "Composition X" 5% White beeswax 10% Liquid Paraffin 30% Benzyl alcohol 5% Purified water (enough to make 100g) (xi) Topical cream 2 weight% "Composition X" 5% Stearic acid 10% Glyceryl monostearate 3% Polyoxyethylene stearyl ether 3% Sorbitol 5% Isopropyl palmitate 2% Methylparaben 0.2% Purified water (enough to make 100g)

[0092] These formulations may be prepared by conventional procedures well known in the pharmaceutical art. It will be understood that the above pharmaceutical compositions may be modified according to well-known pharmaceutical techniques to accommodate different amounts and types of active ingredient "Composition X". Aerosol formulation (vi) may be used in combination with a standard metered dose aerosol dispenser. Furthermore, the specific ingredients and ratios are for illustrative purposes. Ingredients may be substituted with appropriate equivalents and ratios may be varied according to the desired properties of the intended dosage form.

[0093] Although specific embodiments have been described above with reference to disclosed embodiments and examples, such embodiments are merely illustrative and do not limit the scope of the present invention. Changes and modifications may be made by those skilled in the art without departing from the invention in its broader aspects, as defined in the following claims.

[0094] All publications, patents, and patent documents are incorporated herein by reference as if individually incorporated by reference. Any limitations that are inconsistent with this disclosure should not be understood therefrom. The present invention has been described with reference to various specific preferred embodiments and techniques. However, it should be understood that many variations and modifications can be made while remaining within the spirit and scope of the invention.

Claims

1. PAC-1 for treating uveal or cutaneous melanoma: 【Chemistry 1】 and entrectinib, wherein said PAC-1 and said entrectinib are formulated such that they can be administered simultaneously or sequentially to a patient in need thereof in a therapeutically effective amount of PAC-1, and a therapeutically effective amount of entrectinib, wherein said PAC-1 and said entrectinib synergistically treat said melanoma at the dose levels administered, thereby treating said melanoma.

2. PAC-1 in the manufacture of a medicament for treating uveal or cutaneous melanoma in a patient in need of such treatment: 【Chemistry 2】 and entrectinib, wherein said PAC-1 and said entrectinib can be administered simultaneously or sequentially to a patient as a therapeutically effective amount of PAC-1 and a therapeutically effective amount of entrectinib, thereby treating said uveal or cutaneous melanoma.

Citation Information

Patent Citations

  • Procaspase-3 activation by combination therapy

    JP2015509965A

  • PAC-1 combination therapy

    JP2018516936A

  • Combinations for the treatment of cancer

    WO2017106492A1

  • Macrocyclic compounds as ROS1 kinase inhibitors

    WO2018170381A1